Acellular dermal matrix loading with bFGF achieves similar acceleration of bone regeneration to BMP-2 via differential effects on recruitment, proliferation and sustained osteodifferentiation of mesenchymal stem cells

Highlights

• An improved barrier membrane used in the field of bone tissue engineering was proposed, which is acellular dermal matrix (ADM) loaded with growth factors.

• It is generally agreed that BMP-2 and -7 provide the greatest bone regeneration potentials, however, we found that ADM loading with bFGF could guide similar bone regeneration to BMP-2.

• Compared with BMP-2, bFGF could more effectively recruit MSCs and moreover, BMMSCs pretreated by bFGF showed out stronger proliferation at 1-5 days and osteogenic differentiation potentials at 14 days.

Abstract

New generation of barrier membranes has been developed, which not only act as barriers but also as delivery devices to release specific growth factors. This study observed biological behaviors of bone morrow mesenchymal stem cells (BMMSCs) pretreated by bFGF or BMP-2 in vitro and evaluated differential bone regeneration process induced by bFGF and BMP-2 loaded acellular dermal matrix (ADM) membrane using critical-size rat calvarial defect model in vivo. The results showed that the proliferation capability of BMMSCs pretreated by bFGF was stronger than that by BMP-2, while there was temporally differential effect of bFGF and BMP-2 pretreatment on MSC osteogenic differentiation potentials. During healing process of rat calvarial defects, 2-fold more CD34 −/CD90 + MSCs in group of bFGF-ADM was observed than in any other treatment group at 2 weeks. However, there were similar amount of new bone formation and expression of osteopotin in newly-formed bone tissue in groups of bFGF- and BMP-2-ADM at 8 weeks, which were more than those in ADM alone and blank control. Taken together, bFGF-ADM guided similar bone regeneration to BMP-2 through more efficient recruitment of MSCs, and moreover, BMMSCs pretreated by bFGF showed stronger proliferation at 1–5 days and osteogenic differentiation potentials at 14 days compared with BMP-2 pretreatment.